Chronic Kidney Disease

New data from a study performed by investigators at UVA Health details the accuracy of blood glucose measurements with factory-calibrated CGMs in patients undergoing dialysis.

New research from Indiana University details the impact of an invasive management strategy compared to medical management among patients with NSTEMI and chronic kidney disease across the spectrum of CKD severity.

An analysis of 20 randomized clinical trials comparing empagliflozin against placebo therapy in patients with type 2 diabetes suggests use of the SGLT2 inhibitor could reduce risk of developing kidney stones by nearly 40%.

After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.

Hiddo Heerspink, PharmD, PhD, discusses a SURPASS-4 analysis examining kidney outcomes among patients receiving tirzepatide vs insulin glargine and provides perspective on the next steps for research as well as education.

An analysis of SURPASS-4 data presented at ADA 2022 details the apparent reduction in progression of chronic kidney disease observed with use of tirzepatide compared to insulin glargine in the phase 3 trial, with a 41% reduction in progression of CKD in T2D.

Naomi Fisher, MD, offers perspective on the changing landscape of diabetes management and how the addition of new agents to the ADA's Standards of Care might impact care of patients.

An analysis of data from more than 75,000 patients with diabetic kidney disease details the risk of fracture among new users of SGLT2 inhibitors compared to new users of DPP-4 inhibitors.

Analysis of data from more than 75k patients with diabetes in Canada suggests use of SGLT2 inhibitors was not associated with an increased fracture risk compared with DPP-4 inhibitors among patients with diabetic kidney disease.

An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.

A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.

A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

We sat down with Deepak Bhatt, MD, MPH, at ACC.22 to discuss a study he took part in assessing the potential patient population of finerenone using eligibility criteria from FIDELIO-DKD and FIGARO-DKD against information from NHANES.

On March 30, Akieba Therapeutics announced the receipt of a CRL from the FDA for their NDA for vadadustat as a treatment for anemia due to chronic kidney dialysis in adult patients on dialysis and not on dialysis.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. March's month in review features CGM news, calls for insulin co-pay caps, and info on the declining quality of US diets.

A retrospective cohort study suggests use of GLP-1 RAs was associated with a 21% reduction in risk of all-cause mortality in patients with type 2 diabetes and advanced-stage chronic kidney disease compared with DPP-4 inhibitors.

A randomized trial comparing the effects of immediate testing and disclosure versus delayed testing, results suggest disclosing results of APOL1 testing led to reductions in blood pressure and meaningful lifestyle changes among patients with hypertension.

The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.

Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.

New research suggests pregnancies conceived with assisted reproductive technology were associated with a more than doubling in risk for acute kidney injury.

Data from an analysis of more than 150,000 patients suggests increased BMI was associated with more than a 3-fold increase in odds of diabetic nephropathy in patients with type 2 diabetes, but this effect was more apparent in women who experienced a 14-fold increase in odds of diabetic nephropathy.

An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.

New data provides insight into risk factors that could improve risk stratification of prediction models for cardiovascular disease among patients with chronic kidney disease.

An analysis of data from more than 135k patients with type 1 and type 2 diabetes indicates the age-adjusted rate of chronic kidney disease was greater in type 1 diabetes and also sheds light on the rising rate of obesity in type 1 diabetes.

Dr. Gregory Weiss provides perspective on recent data detailing the potential for kidney damage as a result of long-term inhibition of the renin-angiotensin system.

A recent study published in the Journal of the American Society of Nephrology suggests patients with chronic kidney disease have little access to reliable information related to nutrition for patients with chronic kidney disease.

A retrospective cohort analysis of more than 3000 patients with CKD suggests use of MRAs was significantly associated with a reduction in the need for renal replacement therapy.

A 31-person task force has composed and released new multispecialty recommendations for management and diagnosis of diabetes and cardiometabolic disease.

November's endocrine month in review features stories on the Build Back Better Act, a recent review from the IOF, data from Kidney Week 2021, and more.